Company Filing History:
Years Active: 2015
Title: The Innovative Mind of Danny Boutz
Introduction
Danny Boutz is a notable inventor based in Austin, TX, who has made significant contributions to the field of immunology through his innovative patent. With an impressive background in research and development, he continues to pave the way for advancements in antibody technology.
Latest Patents
Danny Boutz holds a patent titled "Proteomic identification of antibodies," which encompasses methods and compositions for identifying candidate antigen-specific variable regions. The patent describes techniques for generating antibodies or antigen-binding fragments that possess specific antigenic properties. Notably, it includes methods for determining the amino acid sequences of serum antibody CDR3 and their abundancy levels. Moreover, it presents approaches for ascertaining nucleic acid sequences of antibody variable region sequences and their frequency in biological samples. This invention ultimately aims to enhance the identification and generation of antibodies that include highly-represented CDR domains.
Career Highlights
Danny Boutz is currently affiliated with the Massachusetts Institute of Technology, where he contributes to groundbreaking research in the field of biotechnology. His work focuses on harnessing the power of antibodies to create more effective medical treatments and diagnostic tools. His single patent showcases his dedication and innovative spirit in advancing the life sciences.
Collaborations
Throughout his career, Danny has had the opportunity to collaborate with esteemed colleagues in the field. Notable among his coworkers are Jason Lavinder and Yariv Wine, who share his passion for biotechnological advancements and innovation.
Conclusion
Danny Boutz exemplifies the spirit of innovation in the realm of antibody research and technology. His pioneering patent reflects his commitment to improving medical science and enhancing our understanding of immune responses. Through his work at the Massachusetts Institute of Technology and with fellow researchers, he continues to inspire the future of biotechnology and the development of new therapeutic options.